- Home
- UTHR
as 01-21-2025 4:00pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 16.1B | IPO Year: | 1999 |
| Target Price: | $378.36 | AVG Volume (30 days): | 280.3K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 22.72 | EPS Growth: | 25.10 |
| 52 Week Low/High: | $208.62 - $417.82 | Next Earning Date: | 02-19-2025 |
| Revenue: | $2,756,200,000 | Revenue Growth: | 25.04% |
| Revenue Growth (this year): | 26.19% | Revenue Growth (next year): | 10.79% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PATUSKY CHRISTOPHER | UTHR | Director | Jan 10 '25 | Sell | $361.39 | 5,000 | $1,808,071.86 | 900 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 6 '25 | Sell | $355.52 | 9,500 | $3,372,360.18 | 620 | |
| Mesa Nilda | UTHR | Director | Dec 30 '24 | Sell | $355.77 | 255 | $90,720.10 | 5,528 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 30 '24 | Sell | $356.45 | 9,500 | $3,387,711.25 | 620 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 23 '24 | Sell | $360.57 | 8,700 | $3,146,489.01 | 620 | |
| SULLIVAN LOUIS W | UTHR | Director | Dec 18 '24 | Sell | $374.38 | 26,209 | $9,781,714.72 | 30,139 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 16 '24 | Sell | $368.16 | 9,439 | $3,492,572.64 | 620 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 9 '24 | Sell | $367.27 | 9,822 | $3,610,755.58 | 620 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Dec 5 '24 | Sell | $374.37 | 7,700 | $2,882,649.00 | 36,710 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 2 '24 | Sell | $371.31 | 10,000 | $3,705,074.31 | 620 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
Zacks
2 days ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks
12 days ago
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Zacks
13 days ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Zacks
13 days ago
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Zacks
14 days ago
UTHR vs. STVN: Which Stock Is the Better Value Option?
MT Newswires
14 days ago
UBS Raises Price Target on United Therapeutics to $475 From $415, Keeps Buy Rating
Zacks
14 days ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.